Browse WDR61

Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm
Domain PF00400 WD domain
Function

Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both indepentently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Required for mono- and trimethylation on histone H3 'Lys-4' (H3K4me3), dimethylation on histone H3 'Lys-79' (H3K4me3). Required for Hox gene transcription. Component of the SKI complex which is thought to be involved in exosome-mediated RNA decay and associates with transcriptionally active genes in a manner dependent on PAF1C.

> Gene Ontology
 
Biological Process GO:0002683 negative regulation of immune system process
GO:0006354 DNA-templated transcription, elongation
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006479 protein methylation
GO:0008213 protein alkylation
GO:0016055 Wnt signaling pathway
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018023 peptidyl-lysine trimethylation
GO:0018205 peptidyl-lysine modification
GO:0030099 myeloid cell differentiation
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031060 regulation of histone methylation
GO:0031062 positive regulation of histone methylation
GO:0032259 methylation
GO:0032784 regulation of DNA-templated transcription, elongation
GO:0032786 positive regulation of DNA-templated transcription, elongation
GO:0032968 positive regulation of transcription elongation from RNA polymerase II promoter
GO:0034243 regulation of transcription elongation from RNA polymerase II promoter
GO:0034729 histone H3-K79 methylation
GO:0034968 histone lysine methylation
GO:0043414 macromolecule methylation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0051568 histone H3-K4 methylation
GO:0051569 regulation of histone H3-K4 methylation
GO:0051571 positive regulation of histone H3-K4 methylation
GO:0080182 histone H3-K4 trimethylation
GO:0198738 cell-cell signaling by wnt
GO:1902275 regulation of chromatin organization
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1905269 positive regulation of chromatin organization
GO:2001160 regulation of histone H3-K79 methylation
GO:2001162 positive regulation of histone H3-K79 methylation
Molecular Function -
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0000785 chromatin
GO:0008023 transcription elongation factor complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0016593 Cdc73/Paf1 complex
GO:0030880 RNA polymerase complex
GO:0035327 transcriptionally active chromatin
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0055087 Ski complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
> KEGG and Reactome Pathway
 
KEGG hsa03018 RNA degradation
Reactome R-HSA-429914: Deadenylation-dependent mRNA decay
R-HSA-8866654: E3 ubiquitin ligases ubiquitinate target proteins
R-HSA-112387: Elongation arrest and recovery
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-74160: Gene Expression
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-8852135: Protein ubiquitination
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-429958: mRNA decay by 3' to 5' exoribonuclease
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WDR61 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WDR61 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WDR61 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5950.0275
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8360.752
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.420.828
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0940.708
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2090.901
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0450.982
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0690.837
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0950.954
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0470.98
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3710.834
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0250.993
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0550.298
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WDR61 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WDR61. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WDR61. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WDR61.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WDR61. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WDR61 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WDR61 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWDR61
NameWD repeat domain 61
Aliases REC14; SKI8; SKI8 homolog; meiotic recombination REC14 protein homolog; recombination protein REC14; WD repe ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WDR61 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.